---
title: 'Regulatory Daily Summary: What Happened on November 14, 2026'
headline: EMA committee backs seven medicines and flags Mounjaro contraception concerns
description: The committee supported 11 indication extensions and a dapivirine vaginal
  ring that lasts three months.
url: https://thebench.bio/news/regulatory/2026-11-14
topic: regulatory
date: '2026-11-14'
covers:
- '2026-11-14'
date_published: '2026-11-14T12:01:19Z'
date_modified: '2026-11-15T00:01:06Z'
tags:
- Industry
sources: 1
publisher: TheBench.Bio
---

# Regulatory Daily Summary: What Happened on November 14, 2026

**EMA committee backs seven medicines and flags Mounjaro contraception concerns**

The committee supported 11 indication extensions and a dapivirine vaginal ring that lasts three months.

## Today in brief

The EMA’s drug committee recommended marketing authorization for seven medicines, including treatments for lung cancer and hypertension. [1] It also adopted a communication about Mounjaro and oral contraceptive reliability, and supported 11 indication extensions. [1]

## EMA committee recommends seven medicines and flags Mounjaro contraception concerns

At its November meeting, the EMA’s Committee for Medicinal Products for Human Use, or CHMP, recommended marketing authorization for seven medicines. [1] The recommendations include Aumseqa for non-small cell lung cancer, Baxfendy for inadequately controlled hypertension, and Zybrivo for non-squamous non-small cell lung cancer in adults. [1]

The committee also backed two insulin-aspart biosimilars, Garzulys and Donrafylix, for diabetes in people aged one year and older. [1] It recommended extending Gazyvaro’s use to adults with active, moderate-to-severe systemic lupus erythematosus not adequately controlled by standard treatment, and Isturisa’s use to children and adolescents aged six and older with endogenous Cushing’s syndrome. [1]

For Mounjaro, the CHMP adopted a communication about possible effects of tirzepatide on oral contraceptive reliability. [1] The communication advises women who could become pregnant to use contraception and says evidence about tirzepatide’s effects on oral contraceptives is limited for women with obesity, overweight, or type 2 diabetes. [1] After the European Commission decides, the authorization holder will distribute the communication to health professionals, and it will appear on EMA and national register websites. [1]

The CHMP recommended indication extensions for 11 medicines, including Gazyvaro and Isturisa. [1] It also backed a 100 mg dapivirine vaginal ring for HIV-1 prevention, which can be replaced every three months instead of monthly. [1] The ring was assessed through the EU-M4All procedure, with WHO experts and regulators from Kenya, South Africa, and Zambia participating. [1]

After re-examining two medicines, the committee maintained its recommendations against authorization. [1]

## The day in numbers

- **7**: Medicines for which the CHMP recommended marketing authorization at its November meeting. [1]
- **11**: Medicines with recommended therapeutic-indication extensions. [1]
- **3 months**: Replacement interval for the recommended 100 mg dapivirine vaginal ring, compared with monthly replacement. [1]

## Also published

- [Weekly reads: more on uniQure, how not to think about aging, mini lenses](<https://ipscell.com/2026/11/weekly-reads-more-on-uniqure-how-not-to-think-about-aging-mini-lenses/?utm_source=rss&utm_medium=rss&utm_campaign=weekly-reads-more-on-uniqure-how-not-to-think-about-aging-mini-lenses>), The Niche
- [BIO’s plan for ‘securing America’s biotech century’](<https://www.biocentury.com/article/661607/bio-s-plan-for-securing-america-s-biotech-century?utm_source=bc_rss&utm_medium=rss>), BioCentury
- [EMA’s CHMP backs new medicines from Hansoh, Innovent, AstraZeneca](<https://www.biocentury.com/article/661606/ema-s-chmp-backs-new-medicines-from-hansoh-innovent-astrazeneca?utm_source=bc_rss&utm_medium=rss>), BioCentury

## Sources

1. [Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 November 2026](<https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026>), EMA Press, 2026-11-13

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2026>
